Drugs / OVX033
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06128382 | Jan → Jul 2024 | Coronaviridae infectious disease | Osivax | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-07-06 | Osivax | Results Osivax Publishes Preclinical Data for Sarbecovirus Vaccine Candidate, OVX033 in Frontiers in Immunology osivax.com ↗
The preclinical data revealed the ability of OVX033 to trigger cross-reactive T-cell responses (especially in the lungs) and notably, cross-protection against three SARS-CoV-2 variants of concern (B.1 Europe, Delta B.1.617.2 and Omicron B.1.1.529). |
| 2022-09-01 | Osivax | Results Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences osivax.com ↗
Preclinical proof of cross-protection against SARS-COV-2 with OVX033 in hamster challenge model to be presented at Options XI |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OVX033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06128382 ↗ |
| Modality | Vaccine | “OVX033 coronavirus vaccine” NCT06128382 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06128382 ↗ |